Screener
BridgeBio Pharma BBIO Unrealized Gains
Unrealized Gains at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:CashEquivalentsUnrealizedGains.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | Amortized Cost Basis | Unrealized Gains | Unrealized Losses | Estimated Fair Value |
|---|---|---|---|---|
| Money market funds | $343,613 | — | — | $343,613 |
| U.S. Treasury securities | 1,998 | — | — | 1,998 |
| Agency discount notes | 32,927 | — | (1) | 32,926 |
| Total cash equivalents | $378,538 | — | $(1) | $378,537 |
| Marketable securities: | ||||
| U.S. Treasury securities | 38,795 | — | (6) | 38,789 |
| Agency discount notes | 3,460 | — | — | 3,460 |
| Total marketable securities | 42,255 | — | (6) | 42,249 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's unrealized gains?
- BridgeBio Pharma (BBIO) reported unrealized gains of $0 in Q2 2026.
- What does unrealized gains mean?
- Unrealized Gains as reported by BridgeBio Pharma, Inc. Common Stock.
Ask your AI about BridgeBio Pharma's unrealized gains.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude